Sélectionner une page

Experimental autoimmune encephalomyelitis kit

SB-PEPTIDE offers you a turnkey solution for your multiple sclerosis (MS) studies with an experimental autoimmune encephalomyelitis kit (EAE kit). Each kit provided allows the induction of EAE in 9 mice (0.2mL/mouse). The kit contains 2.1mL of MOG35-55/CFA emulsion, one vial containing 5µg pertussis toxin (PTX) in glycerol buffer and a recommended experimental protocol with typical results.

 

MOG35-55/CFA emulsion

Myelin Oligodendrocyte Glucoprotein (MOG35-55) is used in emulsion with Complete Freund’s Adjuvant (CFA) in EAE studies. Emulsification is an important step in the success of the study, results will depend on this phase. sb-PEPTIDE proposes to provide you with your MOG/CFA emulsion already pre-filled in ready-to-use syringes.

The complete Freund’s adjuvant is used as an immunopotentiator, It is composed of inactivated and dried mycobacteria and used with MOG to induce EAE. Experimental autoimmune encephalomyelitis is the model commonly used to study efficacy of drugs for treatment of multiple sclerosis (MS) but also pathogenesis of autoimmunity, CNS inflammation, demyelination, cell trafficking and tolerance induction.

Why pre-filled MOG/CFA emulsion ?

Two emulsion preparations that are not exactly equivalent can give very different outcomes. Indeed several critical steps are important, such as quantities used, emulsification time, etc. Pre-filled MOG/CFA emulsion is an ideal solution for your experiments, it provides reliable, reproducible and repeatable results.

Moreover, it saves you precious time when performing your tests.

 

EAE kit specifications

 

Experimental Autoimmune Encephalomyelitis kit MOG35-55 concentration : 1 mg/mL
Mycobacterium tuberculosis concentration: 1 mg/mL
Experimental Autoimmune Encephalomyelitis EAE kit MOG CFA emulsion Each kit provides enough to induce EAE in 9 mice
Experimental Autoimmune Encephalomyelitis  EAE kit for multiple sclerosis The kit contains 3 syringes with 0.7mL of pre-filled MOG/CFA emulsion, one vial containing 5µg pertussis toxin (PTX) in glycerol buffer and a recommended experimental protocol
Mog 35-55 peptide buy MOG35-55 : MEVGWYRSPFSRVVHLYRNGK – Synthesized by SB-PEPTIDE – see MOG35-55 peptide product page

 

Price

Product catalog Size Price € HT Price $ USD
SB036-1KIT 1 kit  450  560

 

References

1-Androutsou, M.-E., Tapeinou, A., Vlamis-Gardikas, A. & Tselios, T. Med. Chem. 14, 120–128 (2018)
Myelin Oligodendrocyte Glycoprotein and Multiple Sclerosis

 

BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) is located on the external surface of myelin, a membranous component of the central nervous system (CNS) that forms the insulating lipid layer around neurons. The major MOG splicing variant (a1 transcript) encodes a transmembrane protein with an extracellular domain of an Ig variable (IgV) fold. MOG IgV domains from the same or different cells dimerize and contribute to the organization and maintenance of the myelin sheath in neurons. The encepalitogenic T cells recognize MOG and its immunodominant epitopes (epitopes 1-22, 35-55 and 92-106 located at the dimer interface) as foreign antigens and cause the destruction of myelin (demyelination) leading to the clinical condition known as multiple sclerosis (MS). Recognition of the antigen takes place in the context of the trimolecular complex formed by HLA, MOGpeptides and TCR.

OBJECTIVE: Understanding the role of MOG in MS.

METHOD/RESULTS: We have reviewed herein, the genomic organization of the human MOG gene, the structural characteristics of the MOG protein, the involvement of MOG in MS and clinical studies for the treatment of MS based on MOG peptide analogues.

CONCLUSION: Conjugates of antigenic MOG peptides to mannan and combinations of antigenic MOG and other peptides chemically linked to cells of the immune system may modify the immune response, alleviating in some cases the symptoms of MS.